These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11951921)

  • 1. Progress towards developing a vaccine for group A streptococcus based on the M protein.
    Good MF
    Intern Med J; 2002 Apr; 32(4):132-3. PubMed ID: 11951921
    [No Abstract]   [Full Text] [Related]  

  • 2. Prospects for a group A streptococcal vaccine.
    McMillan DJ; Chhatwal GS
    Curr Opin Mol Ther; 2005 Feb; 7(1):11-6. PubMed ID: 15732524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection against streptococcal pharyngeal colonization with vaccines composed of M protein conserved regions.
    Fischetti VA; Bessen DE; Schneewind O; Hruby DE
    Adv Exp Med Biol; 1991; 303():159-67. PubMed ID: 1805563
    [No Abstract]   [Full Text] [Related]  

  • 4. The quest for GAS vaccine.
    Pandey M; Good MF
    Oncotarget; 2015 Oct; 6(33):34063-4. PubMed ID: 26485764
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunity to group a streptococcal M proteins: forging a single-edged sword.
    Madoff LC
    Clin Infect Dis; 2005 Oct; 41(8):1123-4. PubMed ID: 16163630
    [No Abstract]   [Full Text] [Related]  

  • 6. The emm-type diversity does not always reflect the M protein genetic diversity--is there a case for designer vaccine against GAS.
    Smeesters PR; Dramaix M; Van Melderen L
    Vaccine; 2010 Jan; 28(4):883-5. PubMed ID: 19963033
    [No Abstract]   [Full Text] [Related]  

  • 7. [Primary prevention of rheumatism: the status and outlook (vaccine)].
    Rotta Y
    Ter Arkh; 1985; 57(11):97-100. PubMed ID: 3909476
    [No Abstract]   [Full Text] [Related]  

  • 8. Differences among group A streptococcus epidemiological landscapes: consequences for M protein-based vaccines?
    Smeesters PR; McMillan DJ; Sriprakash KS; Georgousakis MM
    Expert Rev Vaccines; 2009 Dec; 8(12):1705-20. PubMed ID: 19905872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Demonstration of protection in mice from a lethal challenge of three M serotypes of Streptococcus pyogenes using an M-negative vaccine.
    Chappell JD; Stuart JG
    Vaccine; 1993; 11(6):643-8. PubMed ID: 8322487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategic development of the conserved region of the M protein and other candidates as vaccines to prevent infection with group A streptococci.
    Good MF; Pandey M; Batzloff MR; Tyrrell GJ
    Expert Rev Vaccines; 2015; 14(11):1459-70. PubMed ID: 26485214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlates of Protection for M Protein-Based Vaccines against Group A Streptococcus.
    Tsoi SK; Smeesters PR; Frost HR; Licciardi P; Steer AC
    J Immunol Res; 2015; 2015():167089. PubMed ID: 26101780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis of group A streptococci in mice and efficacy of locally administered streptococcal vaccines.
    Bronze MS; McKinsey DS; Beachey EH; Dale JB
    Trans Assoc Am Physicians; 1988; 101():88-92. PubMed ID: 3077732
    [No Abstract]   [Full Text] [Related]  

  • 13. Group A streptococcus epidemiology and vaccine implications.
    Cohen-Poradosu R; Kasper DL
    Clin Infect Dis; 2007 Oct; 45(7):863-5. PubMed ID: 17806050
    [No Abstract]   [Full Text] [Related]  

  • 14. Group A streptococcal antigens and vaccine potential.
    Kehoe MA
    Vaccine; 1991 Nov; 9(11):797-806. PubMed ID: 1722063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of cryptic epitopes in designing a group A streptococcal vaccine.
    Ozberk V; Pandey M; Good MF
    Hum Vaccin Immunother; 2018; 14(8):2034-2052. PubMed ID: 29873591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular biology of Group A
    Brahmadathan NK
    Indian J Med Microbiol; 2017; 35(2):176-183. PubMed ID: 28681803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based design of broadly protective group a streptococcal M protein-based vaccines.
    Dale JB; Smeesters PR; Courtney HS; Penfound TA; Hohn CM; Smith JC; Baudry JY
    Vaccine; 2017 Jan; 35(1):19-26. PubMed ID: 27890396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Group A streptococcus vaccine may be ready for phase I clinical trials in late 1989.
    Raymond CA
    JAMA; 1988 Nov; 260(19):2778. PubMed ID: 3054182
    [No Abstract]   [Full Text] [Related]  

  • 19. Group A streptococcal vaccines: facts versus fantasy.
    Steer AC; Batzloff MR; Mulholland K; Carapetis JR
    Curr Opin Infect Dis; 2009 Dec; 22(6):544-52. PubMed ID: 19797947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid core peptide technology and group A streptococcal vaccine delivery.
    Olive C; Batzloff MR; Toth I
    Expert Rev Vaccines; 2004 Feb; 3(1):43-58. PubMed ID: 14761243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.